We develop solutions for complex health challenges
We are a biotechnological company dedicated to the research and development of innovative medicines for rare infectious diseases with few or no treatment options.
We are specialized in the design of vaccines, therapeutic antibodies and immunogens, covering the entire development process: proof of concept, preclinical and clinical research, registration procedure and pharmacovigilance.
Investigational treatment for hemolytic uremic syndrome (HUS).
Hemolytic uremic syndrome is a serious illness caused by consuming food or water contaminated with the Shiga toxin-producing Escherichia coli bacteria.
It is a rare disease, which mainly affects boys and girls, and there is still no specific approved treatment in the world.
At Inmunova we are developing an innovative candidate biological drug, with the potential to be the first treatment to block Shiga toxin and prevent severe forms of HUS.
